13248-54-9

Basic information

• Product Name: Cyclohexyl chloroformate
• Synonyms: Cyclohexyl carbonochloridate;carbonochloridicacid,cyclohexylester;CYCLOHEXYL CHLOROFORMATE;chloroformic acid cyclohexyl ester;cyclohcxyl chlrorformate
• CAS NO: 13248-54-9
• Molecular Formula: C₇H₁₁ClO₂
• Molecular Weight: 162.61404
• EINECS: 236-230-5
• Product Categories: Pharmaceutical Intermediates;CHLOROFORMATES;API Intermediate
• Mol File: 13248-54-9.mol
• Article Data: 25

Chemical Properties

• Boiling Point: 87.5℃
• Flash Point: 76.355 °C
• Appearance: /
• Density: 1.15 g/cm³
• Vapor Pressure: 0.387mmHg at 25°C
• Refractive Index: 1.464
• Storage Temp.: Hygroscopic, Refrigerator, under inert atmosphere
• Solubility: Chloroform (Sparingly), Ethyl Acetate (Slightly)
• CAS DataBase Reference: Cyclohexyl chloroformate(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexyl chloroformate(13248-54-9)
• EPA Substance Registry System: Cyclohexyl chloroformate(13248-54-9)

Safety Data

• Statements: 23/24/25-34
• Safety Statements: 26-36/37/39
• RIDADR: 3277
• Hazardous Substances Data: 13248-54-9(Hazardous Substances Data)

Usage

Description

Cyclohexyl chloroformate is a transparent liquid with unique chemical properties that make it a valuable compound in various applications. It is known for its ability to act as a protecting group for amines and indoles in peptide synthesis, which is crucial in the development of pharmaceuticals and other bioactive molecules.

Uses

Used in Pharmaceutical Industry:
Cyclohexyl chloroformate is used as a protecting group for amines and indoles in peptide synthesis. This application is essential for the development of various pharmaceuticals, as it helps in the synthesis of complex peptide structures without unwanted side reactions or degradation of the peptide backbone.
Used in Chemical Synthesis:
In the field of chemical synthesis, Cyclohexyl chloroformate is utilized as a protecting group for amines and indoles. This allows chemists to carry out reactions on other functional groups present in the molecule without affecting the amine or indole groups. This selective protection is vital for the synthesis of complex organic molecules and the development of new materials with specific properties.
Used in Research and Development:
Cyclohexyl chloroformate is also employed in research and development, particularly in the field of biochemistry and molecular biology. It serves as a valuable tool for the synthesis and modification of peptides and other biomolecules, enabling scientists to study their structure, function, and interactions with other molecules in detail.

InChI:InChI=1/C7H11ClO2/c8-7(9)10-6-4-2-1-3-5-6/h6H,1-5H2

Upstream product

• 75-44-5 phosgene 
• 108-93-0 cyclohexanol 
• 32315-10-9 bis(trichloromethyl) carbonate 

Downstream Products

• 4078-59-5 N-cyclohexyloxycarbonyl-glycine 
• 3309-46-4 N-cyclohexyloxycarbonyl-alanine 
• 3309-53-3 N-cyclohexyloxycarbonyl-methionine 
• 542-18-7 cyclohexyl chloride 
• 101730-28-3 carbonic acid-(5-acetyl-[8]quinolyl ester)-cyclohexyl ester 
• 1124-54-5 carbamic acid cyclohexyl ester 
• 1561-49-5 dicyclohexyl peroxydicarbonate 
• 351-79-1 fluorocarbonic acid cyclohexyl ester 
• 3514-03-2 Cyclohexyloxycarbonyl-DL-valin 
• 6421-11-0 Cyclohexyl-o-tolyl-carbonat 
• 91766-85-7 1-chloro-2-cyclohexylbenzene 
• 829-32-3 1-chloro-4-cyclohexylbenzene 
• 27163-66-2 3-cyclohexyl-chlorobenzene 
• 3309-47-5 Cyclohexyloxycarbonyl-DL-leucin 

Relevant articles and documents

-

-

Configurational Statistics of Poly(cyclohexene carbonate)

Conformational characteristics of poly(cyclohexene carbonate) (PCHC) have been investigated via molecular orbital (MO) calculations and NMR experiments on model compounds. The MO energies established through comparison with the NMR experiments were applied to the rotational isomeric state scheme with Bernoulli and Markov stochastic processes to yield configurational properties such as unperturbed characteristic ratio, its temperature coefficient, configurational entropy, tacticity entropy, and coherence number of PCHC chains including various stereosequences. trans-PCHC composed of (R,R)- and/or (S,S)-repeating units prefers a tg+t conformation in the O-CH-CH-O bond sequence of the (R,R)-unit, and its unperturbed characteristic ratio depends considerably on stereoregularity: isotactic, 29, and syndiotactic, 0.83 (in chloroform at 25 °C). cis-PCHC comprising (R,S)- and/or (S,R)-units exclusively adopts either g-g+g+ or g-g-g+ conformation in the O-CH-CH-O bond sequence of the (R,S)-unit partly owing to intramolecular hydrogen bonds, and the dependence of the characteristic ratio of cis-PCHC on stereoregularity would be completely opposite to that of trans-PCHC: isotactic, 0.59, and syndiotactic, 25. In terms of the abovementioned characteristic parameters, properties of PCHCs synthesized so far with stereospecific catalysts are discussed.

Levorotatory meptazinol prodrug as well as preparation method and purpose thereof

The invention provides a levorotatory meptazinol prodrug as well as a preparation method and a purpose thereof, wherein the levorotatory meptazinol prodrug is a compound as shown in a formula I or a stereoisomer, a geometrical isomer, a tautomer, oxynitride, a hydrate, a solvate, a metabolite or a pharmaceutically acceptable salt of the compound as shown in the formula I. The compound is low in hepatic first pass effect and high in bioavailability; a medicine which uses the compound as an active component can be used for treating a neurodegenerative disease or various kinds of acute and chronic pain, such as a wound, postoperative, obstetrical and cancer pain, hemicrania, neuropathic pain and the like.

DEVICE AND PROCESS FOR CONTINUOUS PHOSGENATION

A continuous process for generation of phosgene from CO and Cl2 and consumption of the phosgene thus generated in a liquid-phase reaction so as to form organic products P. The process is implemented in two successive reactors R1 and R2, the first reactor R1 being a reactor for catalytic synthesis of phosgene from CO and Cl2 gas, and the second reactor R2 being a piston reactor, the second reactor R2 being equipped with a mechanical axial agitation device.